Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 257

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 257
---
 that are not solely within the Company’s control, and which are considered
in-substance contingent redemption features (refer to Note 10 for further discussion on the redemption rights of the convertible preferred
D-2 shares). The warrants are subject to revaluation at each balance sheet date until settlement, with revaluations recognized in financial
expense, net in the statements of comprehensive loss.

| l. | Share-based payment transactions: |

The Company accounts for share-based
compensation in accordance with ASC 718, Compensation - Stock Compensation (“ASC 718”), which requires companies to
estimate the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately
expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of comprehensive loss.

The Company recognizes compensation expenses
for the grant-date fair value of its awards granted based on the vesting attribution approach over the requisite service period of each
of the awards, net of estimated forfeitures. The Company estimates forfeitures at the time of grant and revise such estimates, if necessary,
in subsequent periods if actual forfeitures differ from those estimates.

The Company estimates the fair value
of share options granted using the Black-Scholes option pricing model. The option-pricing model requires a number of assumptions, of
which the most significant are the expected share price volatility and the expected option term. Expected share price volatility was
estimated based on volatility of the share price of similar companies in the biotechnology sector. The expected option term represents
the period that the Company’s share options are expected to be outstanding and is determined based on the simplified method until
sufficient historical exercise data will support using expected option term assumptions. The risk-free interest rate is based on the
yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans
to pay dividends.

<div align='center'>F-11</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

| m. | Basic and diluted income (loss) per share: |

The Company’s convertible preferred
shares are participating securities and, as such, the Company computes earnings per share using the two-class method. Under
the two-class method, net income (loss) is allocated between Ordinary Shares and